全文获取类型
收费全文 | 17814篇 |
免费 | 1356篇 |
国内免费 | 500篇 |
专业分类
耳鼻咽喉 | 13篇 |
儿科学 | 2163篇 |
妇产科学 | 71篇 |
基础医学 | 1538篇 |
口腔科学 | 52篇 |
临床医学 | 2332篇 |
内科学 | 3445篇 |
皮肤病学 | 153篇 |
神经病学 | 150篇 |
特种医学 | 184篇 |
外国民族医学 | 5篇 |
外科学 | 189篇 |
综合类 | 2764篇 |
预防医学 | 378篇 |
眼科学 | 54篇 |
药学 | 1287篇 |
7篇 | |
中国医学 | 295篇 |
肿瘤学 | 4590篇 |
出版年
2023年 | 255篇 |
2022年 | 262篇 |
2021年 | 520篇 |
2020年 | 612篇 |
2019年 | 549篇 |
2018年 | 499篇 |
2017年 | 578篇 |
2016年 | 538篇 |
2015年 | 644篇 |
2014年 | 1087篇 |
2013年 | 1161篇 |
2012年 | 877篇 |
2011年 | 1085篇 |
2010年 | 758篇 |
2009年 | 782篇 |
2008年 | 776篇 |
2007年 | 739篇 |
2006年 | 701篇 |
2005年 | 674篇 |
2004年 | 671篇 |
2003年 | 496篇 |
2002年 | 439篇 |
2001年 | 437篇 |
2000年 | 313篇 |
1999年 | 300篇 |
1998年 | 263篇 |
1997年 | 184篇 |
1996年 | 260篇 |
1995年 | 315篇 |
1994年 | 290篇 |
1993年 | 260篇 |
1992年 | 248篇 |
1991年 | 224篇 |
1990年 | 175篇 |
1989年 | 187篇 |
1988年 | 182篇 |
1987年 | 134篇 |
1986年 | 114篇 |
1985年 | 215篇 |
1984年 | 167篇 |
1983年 | 106篇 |
1982年 | 133篇 |
1981年 | 104篇 |
1980年 | 83篇 |
1979年 | 91篇 |
1978年 | 61篇 |
1977年 | 48篇 |
1976年 | 46篇 |
1975年 | 13篇 |
1974年 | 7篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
《Vaccine》2022,40(30):4038-4045
PurposeAs protection from COVID-19 following two doses of the BNT162b2 vaccine showed a time dependent waning, a third (booster) dose was administrated. This study aims to compare the antibody response following the third dose versus the second and to evaluate post-booster seroconversion.MethodsA prospective observational study conducted in Maccabi Healthcare Services. Serial SARS-CoV-2 Spike IgG tests, 1,2,3 and 6 months following the second vaccine dose and one month following the third were obtained. Neutralizing antibody levels were measured in a subset of participants. Per individual SARS-CoV-2 Spike IgG titer ratios were calculated one month after the booster administration compared to titers one month following the second dose and prior to booster.ResultsAmong 110 participants, 56 (51%) were women. Mean age was 61.7 ± 1.9 years and 66 (60%) were immunocompromised. One month after third dose, IgG titers were induced 7.83 (95 %CI 5.25–11.67) folds and 2.40 (95 %CI 1.90–3.03) folds compared to one month after the second, in the immunocompromised and immunocompetent groups, respectively. Of the 17 immunocompromised participants who were seronegative after the second dose, 4 (24%) became seropositive following the third. Comparing the titers prior to the third dose, an increase of 50.7 (95 %CI 32.5–79.1) fold in the immunocompromised group and 25.7 (95 %CI 19.1–34.7) fold in and immunocompetent group, was observed.ConclusionA third BNT162b2 vaccine elicited robust humoral response, superior to the response observed following the second, among immunocompetent and immunocompromised individuals. 相似文献
3.
《Transfusion and apheresis science》2022,61(1):103366
ObjectiveThere is a paucity of data concerning the use of granulocyte colony-stimulating factors (G-CSFs) in pediatric patients with acute lymphoblastic leukemia (ALL). The aim of the present study was to evaluate the effect of G-CSF use on relapse-free and overall survival in 358 consecutive, newly diagnosed pediatric ALL patients uniformly treated at the same institution between April 2012 and April 2020.Materials and MethodsPatients were evaluated in two separate periods, based on the G-CSF treatment approach. All patients who underwent ALL treatment between April 2012 and December 2016 received G-CSF (G-CSF+ arm; n: 245) in the course of the protocol for reducing the risk of febrile neutropenia and/or inducing neutrophil recovery to prevent any treatment delay. No patients after December 2016 received G-CSF, even if they belonged to the high-risk group, and these were included in the G-CSF? arm (n: 113).ResultsEstimated mean relapse-free (106.5 months; 95 % CI 102?110.8 vs 82 months 95 % CI 75.2?88.9; p: 0.794) and overall survival (111.4 months; 95 % CI 108?114.8 vs 85 months 95 % CI 80.4?89.8; p: 0.431) rates were similar between the G-CSF+ and G-CSF? groups.ConclusionsOur findings indicate that G-CSF use during ALL treatment had no effect on relapse rates or overall survival. 相似文献
4.
Ibrahim Aldoss MD Salman Otoukesh MD Jianying Zhang PhD Sally Mokhtari PhD Dat Ngo PharmD Mona Mojtahedzadeh MD Monzr M. Al Malki MD Amandeep Salhotra MD Haris Ali MD Ahmed Aribi MD Karamjeet S. Sandhu MD Shukaib Arslan MD Paul Koller MD Brian Ball MD Forrest Stewart MD Peter Curtin MD Andrew Artz MD Ryotaro Nakamura MD Guido Marcucci MD Stephen J. Forman MD Anthony S. Stein MD Vinod Pullarkat MD 《Cancer》2022,128(3):529-535
5.
7.
8.
《Vaccine》2022,40(7):1001-1009
Vaccination guidelines for dogs and cats indicate that core vaccines (for dogs, rabies, distemper, adenovirus, parvovirus; for cats, feline parvovirus, herpes virus-1, calicivirus) are essential to maintain health, and that non-core vaccines be administered according to a clinician’s assessment of a pet’s risk of exposure and susceptibility to infection. A reliance on individual risk assessment introduces the potential for between-practice inconsistencies in non-core vaccine recommendations. A study was initiated to determine non-core vaccination rates of dogs (Leptospira, Borrelia burgdorferi, Bordetella bronchiseptica, canine influenza virus) and cats (feline leukemia virus) in patients current for core vaccines in veterinary practices across the United States. Transactional data for 5,531,866 dogs (1,670 practices) and 1,914,373 cats (1,661 practices) were retrieved from practice management systems for the period November 1, 2016 through January 1, 2020, deidentified and normalized. Non-core vaccination status was evaluated in 2,798,875 dogs and 788,772 cats that were core-vaccine current. Nationally, median clinic vaccination rates for dogs were highest for leptospirosis (70.5%) and B. bronchiseptica (68.7%), and much lower for canine influenza (4.8%). In Lyme-endemic states, the median clinic borreliosis vaccination rate was 51.8%. Feline leukemia median clinic vaccination rates were low for adult cats (34.6%) and for kittens and 1-year old cats (36.8%). Individual clinic vaccination rates ranged from 0 to 100% for leptospirosis, B. bronchiseptica and feline leukemia, 0–96% for canine influenza, and 0–94% for borreliosis. Wide variation in non-core vaccination rates between clinics in similar geographies indicates that factors other than disease risk are driving the use of non-core vaccines in pet dogs and cats, highlighting a need for veterinary practices to address gaps in patient protection. Failure to implement effective non-core vaccination strategies leaves susceptible dogs and cats unprotected against vaccine-preventable diseases. 相似文献
9.
PI3K-AKT-mTOR通路是人体内重要的信号通路之一,其在控制细胞生长、分化、凋亡和自噬等方面都发挥着重要作用。近年来研究发现,PI3K-AKT-mTOR信号通路与急性髓系白血病(acute myeloid leukemia,AML)的发生发展密切相关。以PI3K-AKT-mTOR 通路为靶点的AML治疗也取得了很大进步。本文就PI3K-AKT-mTOR信号通路的组成、表达、调控以及该信号通路相关抑制剂在AML中的研究进展进行综述,并对今后的研究方向进行展望。 相似文献
10.
Disparity in Utilization of Multiagent Therapy for Acute Promyelocytic Leukemia in the United States
《Clinical Lymphoma, Myeloma & Leukemia》2022,22(5):319-325
BackgroundDespite high rate of cure in acute promyelocytic leukemia (APL) in clinical trials, outcomes in real-world practice are dismal. We utilized National Cancer Database (NCDB) to explore utilization of multiagent therapy in APL and identify any disparities in treatment in real-world practices.Patients and MethodsNCDB categorizes use of systemic chemotherapy into single agent versus multiagent therapy. Some patients received hormonal therapy, immunotherapy, and unknown therapy; details of these treatments could not be ascertained. We therefore used multiple logistic regression analysis to evaluate effects of covariates on the probability of multiagent therapy use in 6678 patients.ResultsCompared to patients >60 years, patients aged 0 to 18 years (hazard ratio[HR] 3.2, 95% confidence interval [CI] 1.8-5.5, P< .0001), 19 to 40 years (HR 1.6, 95% CI 1.03-2.54, P= .03), and 41 to 60 years (HR 1.6, 95% CI 1.3-1.9, P< .0001) were more likely to receive multiagent therapy. Patients with Charlson comorbidity index (CCI) of 0 (HR 1.6, 95% CI 1.2-2.3, P= .001) and CCI of 1 (HR 1.4, 95% CI 1.0-1.9, P= .04) had a higher likelihood of receiving multiagent therapy than patients with CCI ≥ 3. Patients treated at academic cancer centers, compared to those treated at community cancer center (HR 0.5, 95% CI 0.3-0.7, P= .001), comprehensive community cancer center (HR 0.7, 95% CI 0.6-0.8, P< .0001), and integrated network cancer center (HR 0.8, 95% CI 0.6-0.9, P= .02) were more likely to be treated with multiagent therapy. Compared to the patients with private insurance, those with Medicaid had increased likelihood (HR 1.2, 95% CI 1.0-1.4, P= .04) whereas uninsured patients had a lower likelihood of receiving multiagent therapy (HR 0.6, 95% CI 0.5-0.8, P= .0005).ConclusionTo our knowledge, this study is the first and the largest scale analysis of treatment practices in APL in real-world practices. Our findings highlight significant disparities in treatment of APL based on age, insurance, and health-system factors. 相似文献